Exact Sciences marked a -4.1% change today, compared to 1.0% for the S&P 500. Is it a good value at today's price of $70.21? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
-
Exact Sciences belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
-
The company's P/B ratio is 4.07
-
Exact Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -44.4 based on its trailing 12 month price to earnings (EPS) of $-1.58 per share
-
Its forward P/E ratio is -71.6, based on its forward earnings per share (EPS) of $-0.98
-
EXAS has a Price to Earnings Growth (PEG) ratio of -0.55, which shows the company has a fair value when we factor growth into the price to earnings calculus.
-
Over the last four years, Exact Sciences has averaged free cash flows of $-188583000.0, which on average grew 1.7%
-
Exact Sciences has moved 24.4% over the last year compared to 20.7% for the S&P 500 -- a difference of 3.8%
-
EXAS has an average analyst rating of buy and is -24.16% away from its mean target price of $92.58 per share